Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q2 2023 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2023-08-11 · accession 0000902664-23-004379

$75.7M
Reported value
12
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$25.7M33.9%7,050,000CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$12.5M16.6%630,380CommonSOLE
00534A102IVVDINVIVYD INC$9.7M12.8%9,248,250CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$5.2M6.85%197,700CommonSOLE
231269200CURIS INC$5.0M6.58%6,000,000CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$3.7M4.86%346,190CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$3.5M4.68%142,500CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$3.1M4.09%1,910,600CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$2.9M3.78%166,200CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$2.4M3.18%67,400CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$2.0M2.64%363,800CommonSOLE
65344D109NEXIMMUNE INC$37,6040.05%133,442CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.